Login Register Cart 0
Review Article

Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment

Author(s): Ebrahim Mirzajani, Sogand Vahidi, Seyedeh Elham Norollahi and Ali Akbar Samadani*

Volume 11, Issue 1, 2022

Published on: 29 April, 2022

Page: [12 - 24] Pages: 13

DOI: 10.2174/2211536611666220322160242

Price: $65

Abstract

Gastric cancer (GC) is the fourth most frequent disease in the world and the second cause of cancer-related death. In this way, over 80% of diagnoses are made in the middle to advanced degrees of the disease, underscoring the requirement for innovative biomarkers that can be identified quickly. Meaningly, biomarkers that can complement endoscopic diagnosis and be used to detect patients with a high risk of GC are desperately needed. These biomarkers will allow for the accurate prediction of therapy response and prognosis in GC patients, as well as the development of an optimal treatment strategy for each individual. Conspicuously, microRNAs (miRNAs) and small noncoding RNA regulate the expression of target mRNA, thereby modifying critical biological mechanisms. According to the data, abnormally miRNAs expression in GC is linked to tumor growth, carcinogenesis, aggression, and distant metastasis. Importantly, miRNA expression patterns and nextgeneration sequencing (NGS) can also be applied to analyze different kinds of tissues and cancers. Given the high death rates and poor prognosis of GC, and the absence of a clinical diagnostic factor that is adequately sensitive to GC, research on novel sensitive and specific markers for GC diagnosis is critical. In this review, we examine the latest research findings that suggest the feasibility and clinical utility of miRNAs in GC.

Keywords: microRNA, gastric cancer, biomarker, diagnosis, therapeutic target, next generation sequencing (NGS).

« Previous Next »
Graphical Abstract

[1]
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019; 14(1): 26-38.
[http://dx.doi.org/10.5114/pg.2018.80001] [PMID: 30944675]
[2]
Song K, Yang Q, Yan Y, Yu X, Xu K, Xu J. Gastric mucin phenotype indicated aggressive biological behavior in early differentiated gastric adenocarcinomas by endoscopic treatment. 2021. Preprint.
[http://dx.doi.org/10.21203/rs.3.rs-506310/v1]
[3]
Gong EJ, Lee JY, Bae SE, et al. Characteristics of non-cardia gastric cancer with a high serum anti-Helicobacter pylori IgG titer and its asso-ciation with diffuse-type histology. PLoS One 2018; 13(4): e0195264.
[http://dx.doi.org/10.1371/journal.pone.0195264] [PMID: 29621300]
[4]
Talebi A, Mohammadnejad A, Akbari A, et al. Survival analysis in gastric cancer: A multi-center study among Iranian patients. BMC Surg 2020; 20(1): 152.
[http://dx.doi.org/10.1186/s12893-020-00816-6] [PMID: 32660458]
[5]
Vahidi S, Norollahi SE, Agah S, Samadani AA. DNA methylation profiling of hTERT gene alongside with the telomere performance in gas-tric adenocarcinoma. J Gastrointest Cancer 2020; 51(3): 788-99.
[http://dx.doi.org/10.1007/s12029-020-00427-7] [PMID: 32617831]
[6]
Batool A, Hill TDM, Nguyen NT, et al. Altered biogenesis and microRNA content of hippocampal exosomes following experimental status epilepticus. Front Neurosci 2020; 13: 1404.
[http://dx.doi.org/10.3389/fnins.2019.01404] [PMID: 32009885]
[7]
Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 2013; 33(2): 186-92.
[http://dx.doi.org/10.1161/ATVBAHA.112.300139] [PMID: 23325475]
[8]
Mulrane L, Klinger R, McGee SF, Gallagher WM, O’Connor DP. microRNAs: a new class of breast cancer biomarkers. Expert Rev Mol Diagn 2014; 14(3): 347-63.
[http://dx.doi.org/10.1586/14737159.2014.901153] [PMID: 24649821]
[9]
Si Y, Zhang H, Ning T, et al. miR-26a/b inhibit tumor growth and angiogenesis by targeting the HGF-VEGF axis in gastric carcinoma. Cell Physiol Biochem 2017; 42(4): 1670-83.
[http://dx.doi.org/10.1159/000479412] [PMID: 28738343]
[10]
Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014; 33(2): 135-47.
[http://dx.doi.org/10.1038/onc.2013.54] [PMID: 23455326]
[11]
Safi A, Delgir S, Ilkhani K, et al. The expression of miRNA-152-3p and miRNA-185 in tumor tissues versus margin tissues of patients with chemo-treated breast cancer. BMC Res Notes 2021; 14(1): 234.
[http://dx.doi.org/10.1186/s13104-021-05647-z] [PMID: 34134782]
[12]
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
[http://dx.doi.org/10.1101/gr.082701.108] [PMID: 18955434]
[13]
Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 2016; 76(13): 3666-70.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-0359] [PMID: 27325641]
[14]
Vahidi S, Samadani AA. TERRA Gene expression in gastric cancer: Role of hTERT. J Gastrointest Cancer 2021; 52(2): 431-47.
[http://dx.doi.org/10.1007/s12029-020-00565-y] [PMID: 33411257]
[15]
Zhang Z, Li Z, Li Y, Zang A. MicroRNA and signaling pathways in gastric cancer. Cancer Gene Ther 2014; 21(8): 305-16.
[http://dx.doi.org/10.1038/cgt.2014.37] [PMID: 25060632]
[16]
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108(12): 5003-8.
[http://dx.doi.org/10.1073/pnas.1019055108] [PMID: 21383194]
[17]
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13(4): 423-33.
[http://dx.doi.org/10.1038/ncb2210] [PMID: 21423178]
[18]
Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38(20): 7248-59.
[http://dx.doi.org/10.1093/nar/gkq601] [PMID: 20615901]
[19]
Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. Eur Urol 2016; 70(2): 312-22.
[http://dx.doi.org/10.1016/j.eururo.2015.12.054] [PMID: 26806656]
[20]
Cui M, Wang H, Yao X, et al. Circulating microRNAs in cancer: Potential and challenge. Front Genet 2019; 10: 626.
[http://dx.doi.org/10.3389/fgene.2019.00626] [PMID: 31379918]
[21]
Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as novel noninvasive bi-omarkers for hepatocellular carcinoma. Am J Pathol 2016; 186(2): 242-7.
[http://dx.doi.org/10.1016/j.ajpath.2015.10.003] [PMID: 26776075]
[22]
Conev NV, Donev IS, Konsoulova-Kirova AA, Chervenkov TG, Kashlov JK, Ivanov KD. Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. Biosci Trends 2015; 9(6): 393-401.
[http://dx.doi.org/10.5582/bst.2015.01170] [PMID: 26781797]
[23]
Yoda Y, Takeshima H, Niwa T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer 2015; 18(1): 65-76.
[http://dx.doi.org/10.1007/s10120-014-0348-0] [PMID: 24510342]
[24]
Abbasi O, Mashayekhi F, Mirzajani E, Fakhriyeh Asl S, Mahmoudi T, Saeedi Saedi H. Soluble VEGFR1 concentration in the serum of pa-tients with colorectal cancer. Surg Today 2015; 45(2): 215-20.
[http://dx.doi.org/10.1007/s00595-014-0886-4] [PMID: 24676933]
[25]
Yousefi B, Mohammadlou M, Abdollahi M, et al. Epigenetic changes in gastric cancer induction by Helicobacter pylori. J Cell Physiol 2019; 234(12): 21770-84.
[http://dx.doi.org/10.1002/jcp.28925] [PMID: 31169314]
[26]
He C, Chen H, Liu Y, et al. miR-106b-5p promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in osteosar-coma. Exp Ther Med 2020; 19(5): 3203-10.
[http://dx.doi.org/10.3892/etm.2020.8574] [PMID: 32266016]
[27]
Sacconi A, Biagioni F, Canu V, et al. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012; 3(11): e423.
[28]
Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3ζ. Cancer Res 2010; 70(6): 2339-49.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2777] [PMID: 20215506]
[29]
Long JP, Dong LF, Chen FF, Fan YF. miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells. Oncol Lett 2019; 17(2): 1573-80.
[PMID: 30675215]
[30]
Mashayekhi S, Saeidi Saedi H, Salehi Z, Soltanipour S, Mirzajani E. Effects of miR-27a, miR-196a2 and miR-146a polymorphisms on the risk of breast cancer. Br J Biomed Sci 2018; 75(2): 76-81.
[http://dx.doi.org/10.1080/09674845.2017.1399572] [PMID: 29521182]
[31]
Qu Y, Zhang H, Duan J, et al. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer. Oncotarget 2016; 7(22): 33286-96.
[http://dx.doi.org/10.18632/oncotarget.8946] [PMID: 27120811]
[32]
Yang L, Liang H, Wang Y, et al. MiRNA-203 suppresses tumor cell proliferation, migration and invasion by targeting Slug in gastric cancer. Protein Cell 2016; 7(5): 383-7.
[http://dx.doi.org/10.1007/s13238-016-0259-4] [PMID: 27000078]
[33]
Li Z, Lei H, Luo M, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer 2015; 18(1): 43-54.
[http://dx.doi.org/10.1007/s10120-014-0340-8] [PMID: 24481854]
[34]
Wang S, Ma G, Zhu H, et al. miR-107 regulates tumor progression by targeting NF1 in gastric cancer. Sci Rep 2016; 6(1): 36531.
[http://dx.doi.org/10.1038/srep36531] [PMID: 27827403]
[35]
Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol 2012; 29(2): 856-63.
[http://dx.doi.org/10.1007/s12032-011-9823-1] [PMID: 21264532]
[36]
Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by mi-croRNAs. Nature 2008; 455(7209): 58-63.
[37]
Pradhan AK, Emdad L, Das SK, Sarkar D, Fisher PB. The enigma of miRNA regulation in cancer. Adv Cancer Res 2017; 135: 25-52.
[http://dx.doi.org/10.1016/bs.acr.2017.06.001] [PMID: 28882224]
[38]
Macha MA, Seshacharyulu P, Krishn SR, et al. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des 2014; 20(33): 5287-97.
[http://dx.doi.org/10.2174/1381612820666140128213117] [PMID: 24479799]
[39]
Hung PS, Chen CY, Chen WT, et al. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS One 2017; 12(5): e0177346.
[http://dx.doi.org/10.1371/journal.pone.0177346] [PMID: 28486502]
[40]
Tsai MM, Wang CS, Tsai CY, et al. Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer. Eur J Cancer 2016; 64: 137-48.
[http://dx.doi.org/10.1016/j.ejca.2016.05.007] [PMID: 27420607]
[41]
Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 2014; 110(9): 2291-9.
[http://dx.doi.org/10.1038/bjc.2014.119] [PMID: 24595006]
[42]
Huang Z, Zhu D, Wu L, et al. Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev 2017; 26(2): 188-96.
[http://dx.doi.org/10.1158/1055-9965.EPI-16-0607] [PMID: 27756776]
[43]
Jensen S, Lamy P, Rasmussen M, Ostenfeld ML. 638 Dyrskjot, TF Orntoft and CL Andersen, Evaluation of two 639 commercial global miRNA expression profiling platforms for 640 detection of less abundant miRNAs. BMC Genomics 2011; 12(641): 435.
[http://dx.doi.org/10.1186/1471-2164-12-435] [PMID: 21867561]
[44]
Kao H-W, Pan C-Y, Lai C-H, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget 2017; 8(34): 56389-97.
[http://dx.doi.org/10.18632/oncotarget.16916] [PMID: 28915598]
[45]
Cui L, Zhang X, Ye G, et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer 2013; 119(9): 1618-26.
[http://dx.doi.org/10.1002/cncr.27903] [PMID: 23335180]
[46]
Yu X, Luo L, Wu Y, et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013; 30(1): 365.
[http://dx.doi.org/10.1007/s12032-012-0365-y] [PMID: 23307240]
[47]
Zhang X, Cui L, Ye G, et al. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol 2012; 33(6): 2349-55.
[http://dx.doi.org/10.1007/s13277-012-0497-x] [PMID: 22926798]
[48]
Ma M, Chen S, Liu Z, et al. miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer. OncoTargets Ther 2017; 10: 4161-71.
[http://dx.doi.org/10.2147/OTT.S143315] [PMID: 28860826]
[49]
Wang N, Wang L, Yang Y, Gong L, Xiao B, Liu X. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun 2017; 493(3): 1322-8.
[http://dx.doi.org/10.1016/j.bbrc.2017.10.003] [PMID: 28986250]
[50]
Ge J, Chen Z, Li R, Lu T, Xiao G. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progres-sion and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int 2014; 14(1): 128.
[http://dx.doi.org/10.1186/s12935-014-0128-2] [PMID: 25525411]
[51]
Lee SW, Park KC, Kim JG, et al. Dysregulation of MicroRNA-196b-5p and MicroRNA-375 in gastric cancer. J Gastric Cancer 2016; 16(4): 221-9.
[http://dx.doi.org/10.5230/jgc.2016.16.4.221] [PMID: 28053808]
[52]
Halvorsen AR, Sandhu V, Sprauten M, et al. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treat-ed with nivolumab. Acta Oncol 2018; 57(9): 1225-31.
[http://dx.doi.org/10.1080/0284186X.2018.1465585] [PMID: 29683761]
[53]
Zhang W, Wei L, Luo R, Liu H, Chen J. The value of microRNA-21 as a biomarker for the prognosis of lung cancer: A protocol for system-atic review and meta-analysis. Medicine (Baltimore) 2020; 99(33): e21483.
[http://dx.doi.org/10.1097/MD.0000000000021483] [PMID: 32871993]
[54]
Rostamian Delavar M, Baghi M, Safaeinejad Z, Kiani-Esfahani A, Ghaedi K, Nasr-Esfahani MH. Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson’s disease. Gene 2018; 662: 54-65.
[http://dx.doi.org/10.1016/j.gene.2018.04.010] [PMID: 29631008]
[55]
Liep J, Kilic E, Meyer HA, Busch J, Jung K, Rabien A. Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One 2016; 11(6): e0157801.
[http://dx.doi.org/10.1371/journal.pone.0157801] [PMID: 27336447]
[56]
Yuan HL, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. OncoTargets Ther 2018; 11: 3891-900.
[http://dx.doi.org/10.2147/OTT.S156921] [PMID: 30013369]
[57]
Min C, Zhang A, Qin J. Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer. Diagn Pathol 2019; 14(1): 107.
[http://dx.doi.org/10.1186/s13000-019-0882-5] [PMID: 31547835]
[58]
Pan L, Meng Q, Li H, Liang K, Li B. LINC00339 promotes cell proliferation, migration, and invasion of ovarian cancer cells via miR-148a-3p/ROCK1 axes. Biomed Pharmacother 2019; 120: 109423.
[http://dx.doi.org/10.1016/j.biopha.2019.109423] [PMID: 31550677]
[59]
Qiu X, Zhu H, Liu S, et al. Expression and prognostic value of microRNA-26a and microRNA-148a in gastric cancer. J Gastroenterol Hepatol 2017; 32(4): 819-27.
[http://dx.doi.org/10.1111/jgh.13533] [PMID: 27529338]
[60]
Tsai MM, Wang CS, Tsai CY, et al. MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric can-cer. Cancer Lett 2014; 351(2): 222-31.
[http://dx.doi.org/10.1016/j.canlet.2014.06.004] [PMID: 24933454]
[61]
Jin W, Luo W, Fang W, et al. miR-145 expression level in tissue predicts prognosis of patients with esophageal squamous cell carcinoma. Pathol Res Pract 2019; 215(6): 152401.
[http://dx.doi.org/10.1016/j.prp.2019.03.029] [PMID: 31014553]
[62]
Zhu E-D, Li N, Li B-S, et al. miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. PLoS One 2014; 9(8): e106049.
[http://dx.doi.org/10.1371/journal.pone.0106049] [PMID: 25170877]
[63]
Norollahi SE, Alipour M, Rashidy-Pour A, Samadani AA, Larijani LV. Regulatory fluctuation of WNT16 gene expression is associated with human gastric adenocarcinoma. J Gastrointest Cancer 2019; 50(1): 42-7.
[http://dx.doi.org/10.1007/s12029-017-0022-y] [PMID: 29110228]
[64]
Wang Z, Zhao Z, Yang Y, et al. MiR-99b-5p and miR-203a-3p function as tumor suppressors by targeting IGF-1R in gastric cancer. Sci Rep 2018; 8(1): 10119.
[http://dx.doi.org/10.1038/s41598-018-27583-y] [PMID: 29973668]
[65]
Zhao LY, Yao Y, Han J, et al. miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci 2014; 59(8): 1743-53.
[http://dx.doi.org/10.1007/s10620-014-3087-5] [PMID: 24623314]
[66]
Han J, Chen Q. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol 2015; 8(10): 12698-707.
[PMID: 26722459]
[67]
Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010; 9(1): 96.
[http://dx.doi.org/10.1186/1476-4598-9-96] [PMID: 20433742]
[68]
Just C, Knief J, Lazar-Karsten P, et al. MicroRNAs as potential biomarkers for chemoresistance in adenocarcinomas of the esophagogastric junction. J Oncol 2019; 2019: 4903152.
[http://dx.doi.org/10.1155/2019/4903152]
[69]
Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4(1): 79.
[http://dx.doi.org/10.1186/1755-8794-4-79] [PMID: 22112324]
[70]
Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010; 17(8): 523-31.
[http://dx.doi.org/10.1038/cgt.2010.18] [PMID: 20467450]
[71]
Shang Y, Zhang Z, Liu Z, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014; 33(25): 3267-76.
[http://dx.doi.org/10.1038/onc.2013.297] [PMID: 23893241]
[72]
Liu B, Zhou M, Li X, et al. Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer. Cell Death Dis 2021; 12(5): 441.
[http://dx.doi.org/10.1038/s41419-021-03727-3] [PMID: 33947843]
[73]
Zhao X, Hu GF, Shi YF, Xu W. Research progress in microRNA-based therapy for gastric cancer. OncoTargets Ther 2019; 12: 11393-411.
[http://dx.doi.org/10.2147/OTT.S221354] [PMID: 31920330]
[74]
Wald P, Liu XS, Pettit C, et al. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: A review of the literature. Oncotarget 2017; 8(42): 73345-61.
[http://dx.doi.org/10.18632/oncotarget.20277] [PMID: 29069873]
[75]
Hur K, Toiyama Y, Okugawa Y, et al. Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut 2017; 66(4): 654-65.
[http://dx.doi.org/10.1136/gutjnl-2014-308737] [PMID: 26701878]
[76]
Wang J, Huang SK, Zhao M, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 2014; 9(4): e87451.
[http://dx.doi.org/10.1371/journal.pone.0087451] [PMID: 24709885]
[77]
Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prog-nosis. Cells 2020; 9(2): 276.
[http://dx.doi.org/10.3390/cells9020276] [PMID: 31979244]
[78]
Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47(5): 784-91.
[http://dx.doi.org/10.1016/j.ejca.2010.10.025] [PMID: 21112772]
[79]
Jiang Z, Guo J, Xiao B, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 2010; 45(1): 17-23.
[http://dx.doi.org/10.1007/s00535-009-0135-6] [PMID: 19802518]
[80]
Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019; 25(17): 2029-44.
[http://dx.doi.org/10.3748/wjg.v25.i17.2029] [PMID: 31114131]
[81]
Wu X, Tan X, Fu SW. May circulating microRNAs be gastric cancer diagnostic biomarkers? J Cancer 2015; 6(12): 1206-13.
[http://dx.doi.org/10.7150/jca.12535] [PMID: 26535061]
[82]
Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 2012; 7(3): e33608.
[http://dx.doi.org/10.1371/journal.pone.0033608] [PMID: 22432036]
[83]
Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: Molecular markers for gastric cancer. Mol Med Rep 2012; 5(6): 1514-20.
[PMID: 22406928]
[84]
Wen XQ, Qian XL, Sun HK, et al. MicroRNAs: Multifaceted regulators of colorectal cancer metastasis and clinical applications. OncoTargets Ther 2020; 13: 10851-66.
[http://dx.doi.org/10.2147/OTT.S265580] [PMID: 33149603]
[85]
Wu WY, Xue XY, Chen ZJ, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroenterol 2011; 17(31): 3645-51.
[http://dx.doi.org/10.3748/wjg.v17.i31.3645] [PMID: 21987613]
[86]
Chen L, Jiang M, Yuan W, Tang H. Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastroenterol Belg 2012; 75(1): 22-7.
[PMID: 22567743]
[87]
Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010; 6(3): e1000879.
[http://dx.doi.org/10.1371/journal.pgen.1000879] [PMID: 20300657]
[88]
Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the prolifera-tion of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17(9): 2725-33.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2132] [PMID: 21220473]
[89]
Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11(2): 136-46.
[http://dx.doi.org/10.1016/S1470-2045(09)70343-2] [PMID: 20022810]
[90]
Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009; 34(2): 537-42.
[PMID: 19148490]
[91]
Chan SH, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res 2008; 28(2A): 907-11.
[PMID: 18507035]
[92]
Tsai KW, Liao YL, Wu CW, et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 2012; 51(4): 394-401.
[http://dx.doi.org/10.1002/gcc.21924] [PMID: 22420029]
[93]
Xiao B, Zhu E-D, Li N, et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep 2012; 27(2): 559-66.
[PMID: 22020746]
[94]
Chen Y, Song Y, Wang Z, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010; 14(7): 1170-9.
[http://dx.doi.org/10.1007/s11605-010-1202-2] [PMID: 20422307]
[95]
Song YX, Yue ZY, Wang ZN, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by in-hibiting cell proliferation. Mol Cancer 2011; 10(1): 1-13.
[http://dx.doi.org/10.1186/1476-4598-10-1] [PMID: 21205300]
[96]
Zhang Y, Guo J, Li D, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol 2010; 27(3): 685-9.
[http://dx.doi.org/10.1007/s12032-009-9269-x] [PMID: 19598010]
[97]
Su Y, Ni Z, Wang G, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol 2012; 13(4): 468-75.
[http://dx.doi.org/10.1016/j.intimp.2012.05.016] [PMID: 22683180]
[98]
Liu K, Qian T, Tang L, Wang J, Yang H, Ren J. Decreased expression of microRNA let-7i and its association with chemotherapeutic re-sponse in human gastric cancer. World J Surg Oncol 2012; 10(1): 225.
[http://dx.doi.org/10.1186/1477-7819-10-225] [PMID: 23107361]
[99]
Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int J Oncol 2011; 39(5): 1253-64.
[http://dx.doi.org/10.3892/ijo.2011.1112] [PMID: 21743960]
[100]
Wang M, Gu H, Qian H, et al. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. Eur J Cancer 2013; 49(8): 2010-21.
[http://dx.doi.org/10.1016/j.ejca.2012.12.017] [PMID: 23333058]
[101]
Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010; 59(5): 579-85.
[http://dx.doi.org/10.1136/gut.2008.175497] [PMID: 19951901]
[102]
Liu K, Li G, Fan C, Diao Y, Wu B, Li J. Increased Expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012; 40(2): 467-74.
[http://dx.doi.org/10.1177/147323001204000208] [PMID: 22613407]
[103]
Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-85.
[http://dx.doi.org/10.3748/wjg.v17.i35.3976] [PMID: 22046085]
[104]
Chen W, Tang Z, Sun Y, et al. miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. Exp Ther Med 2012; 3(2): 351-6.
[http://dx.doi.org/10.3892/etm.2011.411] [PMID: 22969895]
[105]
Yan Z, Xiong Y, Xu W, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One 2012; 7(7): e40037.
[http://dx.doi.org/10.1371/journal.pone.0040037] [PMID: 22802949]
[106]
Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer pa-tients following surgical resection. Ann Oncol 2011; 22(10): 2257-66.
[http://dx.doi.org/10.1093/annonc/mdq758] [PMID: 21343377]
[107]
Nguyen HT, Kacimi SEO, Nguyen TL, et al. MiR-21 in the cancers of the digestive system and its potential role as a diagnostic, predictive, and therapeutic biomarker. Biology (Basel) 2021; 10(5): 417.
[http://dx.doi.org/10.3390/biology10050417] [PMID: 34066762]
[108]
Zhou X, Zhu W, Li H, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: A microRNA expression analysis. Sci Rep 2015; 5(1): 11251.
[http://dx.doi.org/10.1038/srep11251] [PMID: 26059512]
[109]
Hiyoshi Y, Watanabe M. MicroRNAs in gastrointestinal cancer: A novel biomarker and its clinical application. J Cancer Metastasis Treat 2015; 1: 144-55.
[http://dx.doi.org/10.4103/2394-4722.161617]
[110]
Shao L, Lu X, Zhou Y, et al. Altered miR-93-5p/miR-18a expression in serum for diagnosing non-small cell lung cancer. Am J Transl Res 2021; 13(5): 5073-9.
[PMID: 34150094]
[111]
Stigbrand T. Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. Tumour Biol 2014; 35(12): 12119-25.
[112]
Cheng ZX, Song YX, Wang ZY, Wang Y, Dong Y. miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur Rev Med Pharmacol Sci 2017; 21(18): 4079-86.
[PMID: 29028093]
[113]
Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem 2014; 6(17): 1967-84.
[http://dx.doi.org/10.4155/fmc.14.116] [PMID: 25495987]
[114]
Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet 2019; 10: 478.
[http://dx.doi.org/10.3389/fgene.2019.00478] [PMID: 31156715]
[115]
Soltani TB, Mirzajani E, Fallahi S, et al. Challenging TaqMan probe-based real-time PCR and loop-mediated isothermal amplification (LAMP): The two sensitive molecular techniques for the detection of toxoplasmosis, a potentially dangerous opportunistic infection in im-munocompromised patients. Arch Microbiol 2020; 202(7): 1881-8.
[http://dx.doi.org/10.1007/s00203-020-01903-1] [PMID: 32448961]
[116]
Zununi VS, Barzegari A, Rahbar SY, Mohammadi S, Samadi N. A microRNA isolation method from clinical samples. Bioimpacts 2016; 6(1): 25-31.
[http://dx.doi.org/10.15171/bi.2016.04] [PMID: 27340621]
[117]
all kits are created equal. BMC Biotechnol 2018; 18(1): 16.
[http://dx.doi.org/10.1186/s12896-018-0421-6] [PMID: 29548320]
[118]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 2018; 9: 402.
[http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]
[119]
Simkin A, Geissler R, McIntyre AB, Grimson A. Evolutionary dynamics of microRNA target sites across vertebrate evolution. PLoS Genet 2020; 16(2): e1008285.
[http://dx.doi.org/10.1371/journal.pgen.1008285] [PMID: 32012152]
[120]
Lu G, Ma Y, Jia C, et al. Reduced miR-125a levels associated with poor survival of patients with hepatocellular cancer. Oncol Lett 2017; 14(5): 5952-8.
[http://dx.doi.org/10.3892/ol.2017.6902] [PMID: 29113231]
[121]
Pudova EA, Krasnov GS, Nyushko KM, et al. miRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer. BMC Med Genomics 2020; 13(8)(Suppl. 8): 129.
[http://dx.doi.org/10.1186/s12920-020-00788-9] [PMID: 32948204]
[122]
Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011; 6(6): e20769.
[http://dx.doi.org/10.1371/journal.pone.0020769] [PMID: 21698099]
[123]
Glinge C, Clauss S, Boddum K, et al. Stability of circulating blood-based microRNAs–pre-analytic methodological considerations. PLoS One 2017; 12(2): e0167969.
[http://dx.doi.org/10.1371/journal.pone.0167969] [PMID: 28151938]
[124]
Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 2013; 20(3)(Suppl. 3): S397-405.
[http://dx.doi.org/10.1245/s10434-012-2600-3] [PMID: 22956063]
[125]
Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clin Epigenetics 2018; 10(1): 59.
[http://dx.doi.org/10.1186/s13148-018-0492-1] [PMID: 29713393]
[126]
Giuliani A, Gaetani S, Sorgentoni G, et al. Circulating inflamma-miRs as Potential biomarkers of cognitive impairment in patients affected by Alzheimer’s Disease. Front Aging Neurosci 2021; 13: 647015.
[http://dx.doi.org/10.3389/fnagi.2021.647015] [PMID: 33776746]
[127]
Zekri A-RN, Youssef ASE-D, Lotfy MM, et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS One 2016; 11(5): e0154130.
[http://dx.doi.org/10.1371/journal.pone.0154130] [PMID: 27135244]
[128]
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012; 10(1): 186.
[http://dx.doi.org/10.1186/1479-5876-10-186] [PMID: 22954417]
[129]
Yao Y, Ding Y, Bai Y, et al. Identification of serum circulating MicroRNAs as novel diagnostic biomarkers of gastric cancer. Front Genet 2020; 11: 591515.
[PMID: 33597967]
[130]
Quirico L, Orso F. The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies. Cancer Drug Resist 2020; 3(2): 117-39.
[http://dx.doi.org/10.20517/cdr.2019.103]
[131]
Wang WN, Chen Y, Zhang YD, Hu TH. The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and pro-gression of gastric cancer. Tumour Biol 2013; 34(3): 1865-71.
[http://dx.doi.org/10.1007/s13277-013-0728-9] [PMID: 23519840]
[132]
Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 2013; 30(1): 452.
[http://dx.doi.org/10.1007/s12032-012-0452-0] [PMID: 23307259]
[133]
Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer 2013; 108(4): 932-40.
[http://dx.doi.org/10.1038/bjc.2013.30] [PMID: 23385731]
[134]
Liu H, Zhu L, Liu B, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012; 316(2): 196-203.
[http://dx.doi.org/10.1016/j.canlet.2011.10.034] [PMID: 22169097]
[135]
Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 2013; 108(2): 89-92.
[http://dx.doi.org/10.1002/jso.23358] [PMID: 23733518]
[136]
Li B, Zhao Y, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012; 7(7): e416219.
[http://dx.doi.org/10.1371/journal.pone.0041629]
[137]
Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer 2012; 106(4): 740-7.
[http://dx.doi.org/10.1038/bjc.2011.588] [PMID: 22262318]
[138]
Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102(7): 1174-9.
[http://dx.doi.org/10.1038/sj.bjc.6605608] [PMID: 20234369]
[139]
Esposti DD, Hernandez-Vargas H, Voegele C, et al. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget 2016; 7(22): 31862-77.
[http://dx.doi.org/10.18632/oncotarget.7364] [PMID: 26887054]
[140]
Yu F, Zheng J, Mao Y, et al. Long non-coding RNA growth arrest-specific transcript 5 (GAS5) inhibits liver fibrogenesis through a mecha-nism of competing endogenous RNA. J Biol Chem 2015; 290(47): 28286-98.
[http://dx.doi.org/10.1074/jbc.M115.683813] [PMID: 26446789]
[141]
Huang YK, Yu JC. Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review. World J Gastroenterol 2015; 21(34): 9863-86.
[http://dx.doi.org/10.3748/wjg.v21.i34.9863] [PMID: 26379393]
[142]
Xie X, Tang B, Xiao Y-F, et al. Long non-coding RNAs in colorectal cancer. Oncotarget 2016; 7(5): 5226-39.
[http://dx.doi.org/10.18632/oncotarget.6446] [PMID: 26637808]
[143]
Sun M, Nie F, Wang Y, et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res 2016; 76(21): 6299-310.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-0356] [PMID: 27651312]
[144]
Sun TT, He J, Liang Q, et al. LncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov 2016; 6(7): 784-801.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0921] [PMID: 27147598]
[145]
Liu Y, Sun M, Xia R, et al. Linc HOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell death & disease 2015; 6(7): e1802-.
[146]
Cantile M, Di Bonito M, Tracey De Bellis M, Botti G. Functional interaction among lncRNA HOTAIR and microRNAs in cancer and other human diseases. Cancers 2021; 13(3): 570.
[http://dx.doi.org/10.3390/cancers13030570] [PMID: 33540611]
[147]
Yang F, Xue X, Zheng L, et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J 2014; 281(3): 802-13.
[http://dx.doi.org/10.1111/febs.12625] [PMID: 24397586]
[148]
Xu T-P, Wang Y-F, Xiong W-L, et al. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. Cell death & disease 2017; 8(6): e2837.
[149]
Cao MX, Jiang YP, Tang YL, Liang XH. The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget 2017; 8(7): 12472-83.
[http://dx.doi.org/10.18632/oncotarget.13957] [PMID: 27992370]
[150]
Lü MH, Tang B, Zeng S, et al. Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene 2016; 35(27): 3524-34.
[http://dx.doi.org/10.1038/onc.2015.413] [PMID: 26549025]
[151]
Yi K, Hou M, Yuan J, et al. LncRNA PVT1 epigenetically stabilizes and post-transcriptionally regulates FOXM1 by acting as a microRNA sponge and thus promotes malignant behaviors of ovarian cancer cells. Am J Transl Res 2020; 12(6): 2860-74.
[PMID: 32655815]
[152]
Kong R, Zhang EB, Yin DD, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 2015; 14(1): 82.
[http://dx.doi.org/10.1186/s12943-015-0355-8] [PMID: 25890171]

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy